Saturday, 30 June 2012

Cytograft Tissue Engineering - Product Pipeline Analysis

Cytograft Tissue Engineering, Inc. (CTE) is a medical device company, based in the US. The company develops cell-based solutions to cardiovascular disease. Its product line includes TEBV (Tissue Engineered Blood Vessel), covered stent, patch, percutaneous bypass and valve. CTE’s follow-on products include the LifeGuar patch and the LifeJacket stent-graft. LifeLine is a versatile technology that has the potential to be used for coronary bypass, as a peripheral graft for the prevention of lower limb amputation, or as an arterio-venous shunt for hemodialysis access. It has collaborations with physicians and scientists from Stanford University, the University of Washington, the Minneapolis Heart Institute, the Hope Heart Institute, and the University of Missouri. CTE is headquartered in Novato, California, the US.

This report is a source for data, analysis and actionable intelligence on the Cytograft Tissue Engineering, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.